This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Frick, R. W. Articles by Frick, R. W. Search for Related Content PubMed PubMed Citation Articles by Frick, R. W. Articles by Frick, R. W. Social Bookmarking                         What's this?

Three Treatments for Chronic Venous Insufficiency: Escin, Hydroxyethylrutoside, and Daflon

Robert W. Frick, PhD

10 Brooklyn Avenue Stony Brook, NY 11790

Escin, hydroxyethylrutoside (HR), and Daflon have been shown to be safe and effective for the treatment of chronic venous insufficiency (CVI). They seem to work differently than compression therapy, suggesting that they would usefully augment this therapy. All three phlebotonics attenuate the drop in adenosine triphosphate in venous endothelial cells during hypoxia. This attenuates (1) the inflammation response, (2) the attraction of neutrophils, (3) damage to the veins, and (4) the release of growth factors. These factors otherwise would perpetuate venous insufficiency and contribute to varicose veins. Additional independent effects that would be useful for the treatment of CVI are that they reduce permeability and fragility; HR, Daflon, and perhaps escin increase venous tone; escin inhibits hyaluronidase; Daflon and probably HR are attracted to the veins. With regard to similarity, no differences in effect have been established among these phlebotonics.

Angiology, Vol. 51, No. 3, 197-205 (2000)
DOI: 10.1177/000331970005100303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. R Vazquez, A. Freeman, R. C VanWoerkom, and M. T Rondina Contemporary Issues in the Prevention and Management of Postthrombotic Syndrome Ann. Pharmacother., November 1, 2009; 43(11): 1824 - 1835. [Abstract] [Full Text] [PDF]

				J. J. Bergan, G. W. Schmid-Schonbein, and S. Takase Therapeutic Approach to Chronic Venous Insufficiency and its Complications: Place of Daflon(R) 500 mg Angiology, August 1, 2001; 52(1_suppl): S43 - S47. [Abstract] [PDF]